title: Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors.
abstract: The physiological role of the P2Y(6) nucleotide receptor may involve cardiovascular, immune and digestive functions based on the receptor tissue distribution, and selective antagonists for this receptor are lacking. We have synthesized a series of symmetric aryl diisothiocyanate derivatives and examined their ability to inhibit phospholipase C (PLC) activity induced by activation of five subtypes of recombinant P2Y receptors. Several derivatives were more potent at inhibiting action of UDP at both human and rat P2Y(6) receptors expressed in 1321N1 human astrocytes than activation of human P2Y(1), P2Y(2), P2Y(4) and P2Y(11) receptors. The inhibition by diisothiocyanate derivatives of 1,2-diphenylethane (MRS2567) and 1,4-di-(phenylthioureido) butane (MRS2578) was concentration-dependent and insurmountable, with IC(50) values of 126+/-15 nM and 37+/-16 nM (human) and 101+/-27 nM and 98+/-11 nM (rat), respectively. A derivative of 1,4-phenylendiisothiocyanate (MRS2575) inhibited only human but not rat P2Y(6) receptor activity. MRS2567 and MRS2578 at 10microM did not affect the UTP (100nM)-induced responses of cells expressing P2Y(2) and P2Y(4) receptors, nor did they affect the 2-methylthio-ADP (30nM)-induced responses at the P2Y(1) receptor or the ATP (10microM)-induced responses at the P2Y(11) receptor. Other antagonists displayed mixed selectivities. The selective antagonists MRS2567, MRS2575 and MRS2578 (1microM) completely blocked the protection by UDP of cells undergoing TNFalpha-induced apoptosis. Thus, we have identified potent, insurmountable antagonists of P2Y(6) receptors that are selective within the family of PLC-coupled P2Y receptors.
authors.affiliation: Laboratory of Bioorganic Chemistry, Molecular Recognition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD 20892-0810, USA.
authors.forename: Liaman K
authors.initials: LK
authors.lastname: Mamedova
authors.forename: Bhalchandra V
authors.initials: BV
authors.lastname: Joshi
authors.forename: Zhan-Guo
authors.initials: ZG
authors.lastname: Gao
authors.forename: Ivar
authors.initials: I
authors.lastname: von Kügelgen
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Jacobson
mesh_terms: D000818:Animals; D001665:Binding Sites; D016466:CHO Cells; D006224:Cricetinae; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism*; D058919:Purinergic P2 Receptor Antagonists; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors; D018048:Receptors, Purinergic P2; D013861:Thiocyanates / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D007295:Inositol Phosphates; D058919:Purinergic P2 Receptor Antagonists; D043562:Receptors, G-Protein-Coupled; D018048:Receptors, Purinergic P2; D013861:Thiocyanates; C099845:purinoceptor P2Y6